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Abstract
Background: N-alkylamides (NAAs) are a large group of secondary metabolites occurring in more than 25 plant families
which are often used in traditional medicine. A prominent active NAA is spilanthol. The general goal was to quantitatively
investigate the gut mucosa and blood-brain barrier (BBB) permeability pharmacokinetic properties of spilanthol.
Methods: Spilanthes acmella (L.) L. extracts, as well as purified spilanthol were used to investigate (1) the permeation of
spilanthol through a Caco-2 cell monolayer in vitro, (2) the absorption from the intestinal lumen after oral administration
to rats, and (3) the permeation through the BBB in mice after intravenous injection. Quantification of spilanthol was
performed using a validated bio-analytical UPLC-MS2 method.
Results: Spilanthol was able to cross the Caco-2 cell monolayer in vitro from the apical-to-basolateral side and from the
basolateral-to-apical side with apparent permeability coefficients Papp between 5.2 · 10
−5 and 10.2 · 10−5 cm/h. This in vitro
permeability was confirmed by the in vivo intestinal absorption in rats after oral administration, where an elimination rate
constant ke of 0.6 h
−1 was obtained. Furthermore, once present in the systemic circulation, spilanthol rapidly penetrated
the blood-brain barrier: a highly significant influx of spilanthol into the brains was observed with a unidirectional influx
rate constant K1 of 796 μl/(g · min).
Conclusions: Spilanthol shows a high intestinal absorption from the gut into the systemic circulation, as well as a high
BBB permeation rate from the blood into the brain.
Keywords: Plant N-alkylamide spilanthol, Caco-2 cells, Oral absorption, Blood-brain barrier
Background
N-alkylamides (NAAs) are a large group of secondary me-
tabolites occurring in more than 25 plant families, often
used in traditional medicine and claimed to possess a di-
verse range of pharmacological activities such as antimicro-
bial, analgesic and anti-inflammatory properties [1–8]. The
NAAs consist of a short-chain amine linked to an aliphatic
chain of poly-unsaturated fatty acids through a central
peptide amide bond. Spilanthol (affinin; deca-2E,6Z,8E-
trienoic acid isobutylamide; F3M1 according to the
FxMy classification of NAAs) is a highly abundant and
biologically potent triene NAA found in Asteracea
plants such as Spilanthes acmella. Traditionally, Spi-
lanthes acmella plants are not only used as a food spice,
in toothpastes and cosmetics, but have also been used in
folk medicine for the treatment of toothaches, stomatitis,
rheumatism, fever, funal skin infections and diverse pain
and neuropathic disorders [8]. The pharmacological cen-
tral nervous system (CNS) activity and physiological
mechanisms of spilanthol are only fragmentary docu-
mented. Chakraborty et al. [9] and Barman et al. [10] re-
ported a central analgesic activity of a subcutaneously
Spilanthes acmella extract in an in vivo rat tail flick ex-
periment. Rios et al. [11] showed that a Heliopsis longipes
extract, in which spilanthol was the main active com-
pound, evoked cortical GABA (gamma-aminobutyric acid)
release in an ex vivo in vitro mice brain-tissue study.
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In order to exert these CNS effects, these compounds
must be able to cross several physiological barriers in the
human body. Using in vitro Franz diffusion cell (FDC) ex-
periments, it has already been shown that the N-alkyla-
mide spilanthol can permeate the human skin and pig oral
mucosa, reaching the systemic circulation after topical ap-
plication [12–14]. The permeability coefficient Kp,aq was
3.31 · 10−3 cm/h for human skin and 11.3 · 10−3 cm/h for
the porcine buccal mucosa.
After oral administration, compounds must be able
to pass through the intestinal barrier to reach the sys-
temic circulation. Matthias et al. [15] investigated the
transport of mainly diene N-alkylamides from Echin-
acea (E. angustifolia and E. purpurea root) through a
Caco-2 cell monolayer, which is a model of the intes-
tinal barrier, and found that after 90 min, more than
50 % of the NAAs permeated through the monolayer.
Once present in the blood by passsage through the skin
or mucosa, compounds can cross the blood-brain barrier
to exert central nervous system effects. This entry of com-
pounds into the brain is strictly regulated and controlled:
the BBB forms not only a physical barrier (tight junctions),
but also a transport and metabolic barrier (enzymes) to
maintain an adequate microenvironment of the neuronal
cells [16]. A previous study indicated that tetraene NAAs
from Echinacea appeared in the brains after a single oral
dose of 2.5 mg/kg to rats [17].
Up till now, there is no information about the transport
kinetics of the 2,6,8-triene N-alkylamide spilanthol through
the intestinal barrier after oral application and through the
blood-brain barrier, once present in the blood. Therefore,
the aim of this study was to quantitatively investigate the
intestinal permeability (in vitro Caco-2 cell monolayer and
in vivo oral gavage rat model) and the BBB transport kinet-
ics (in vivo mice model) of spilanthol. Moreover, the distri-
bution of spilanthol within the BBB, i.e. brain parenchyma
versus endothelial cells, was investigated.
Methods
Chemicals and reagents
Ultrapure water (H2O) of 18.2 MΩ.cm quality was pro-
duced by an Arium 611 purification system (Sartorius,
Göttingen, Germany). Vitamin E-TPGS, Hanks’ Bal-
anced Salt Solution (HBSS), trypan blue, potassium
chloride (KCl), dimethylsulfoxide (DMSO), phosphate
buffered saline (PBS), sodium chloride (NaCl), cal-
cium chloride dehydrate (CaCl2.2H2O), sodium lac-
tate, dichloromethane, sodium hydrogen carbonate
(NaHCO3), sodium sulphate (Na2SO4), sodium dihydrogen
phosphate (NaH2PO4), hydrochloric acid (HCl) and ureth-
ane were purchased from Sigma-Aldrich (Diegem, Belgium),
while bovine serum albumin (BSA), disodium hydrogen
phosphate dehydrate (Na2HPO4.2H2O), sodium dihydrogen
phosphate monohydrate (NaH2PO4.H2O), sodium hydrogen
carbonate and absolute ethanol (≥99.9 % V/V) were ob-
tained from Merck KGaA (Darmstadt, Germany). Absolute
ethanol (99.8 % V/V), HPLC gradient grade methanol
(MeOH) and acetonitrile (ACN) came from Fisher Sci-
entific (Erembodegem, Belgium). Dextran was obtained
from AppliChem GmbH (Darmstadt, Germany). UPLC-
MS grade MeOH and ACN were bought from Biosolve
(Valkenswaard, the Netherlands). Phosphoric acid
(85 %) (H3PO4) and dimethylacetamide were purchased
from Jansen Chimica (Geel, Belgium). Trypsin-EDTA was
obtained from Invitrogen (Ghent, Belgium). Calcium
dichloride (CaCl2), LC-MS grade formic acid (FA), poly-
ethylene glycol 400 (PEG 400), tween 80, D-glucose, so-
dium hydroxide (NaOH) and HEPES were purchased at
Fluka (Diegem, Belgium) while propylene glycol (PG) was
bought from Riedel-de Haën (Seelze-Hannover, Germany).
Triethylamine, decanoyl chloride and isobutylamine were
purchased at Acros Organics (Geel, Belgium). The BBB-
positive control dermorphin was purchased at Bachem
(Bubendorf, Switzerland). NMR solvents were bought
from Eurisotop (Saint-Aubin, France).
Products examined
The ethanolic Spilanthes acmella (L.) L. flowers extract
(batch 0001853516, 30 % w/w spilanthol in ethanol) was
obtained from Robertet (Grasse, France) and was used for
the BBB transport assay. Spilanthes acmella (L.) L. is also
known as Akarkara (local name) and Para Cress (English
name). HPLC analysis confirmed the spilanthol content,
as well as a small quantity (9 %) of other NAAs [14]. The
Spilanthes acmella (L.) L. extract (A. Vogel, label claim in-
dicated 2 % w/w dry residue of extracts in 69 % V/V etha-
nol; internal assay: 0.11 % w/w spilanthol, purity >90 %)
came from Bioforce AG (Switzerland) and was used for
the oral gavage experiment.
Purified spilanthol was used for the Caco-2 cell perme-
ability assay. Semi-preparative HPLC was used for its puri-
fication as follows: the Spilanthes acmella (L.) L. extract of
Robertet was dissolved in 30:70 (V/V) H2O:ethanol and fil-
tered using a 0.45 μm nylon HPLC filter (Whatman). One
ml of this solution was injected on a Vydac C18 mono-
meric semi-preparative column (Grace, 250 mm x 10 mm,
5 μm particle size, 300 Å pore size) using a Waters HPLC,
equipped with a Waters 2487 Dual Absorbance Detector.
The sample compartment and column temperature were
maintained at room temperature. An isocratic elution
mode was used with a 50:50 (V/V) A:B (A: 0.1 % FA in
H2O and B: 0.1 % FA in MeOH) mobile phase. A flow rate
of 6.0 ml/min was used and UV detection was performed
at 237 nm. Fractions between 16 and 32 min retention
time were collected and lyophilized using a Christ Gamma
1–16 LSC freeze-dryer (Q-lab, Vilvoorde, Belgium). The
purity of the isolated spilanthol was determined by analyt-
ical HPLC-UV at 237 nm [12] and was 99.9 %.
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As analytical internal standard (IS) in the bio-analytics,
isobutyldecanamide was used and synthesised as described
in Fig. 1. The NMR spectra of this internal standard can
be retrieved in Additional file 1.
Triethylamine (6.0 mmol, 608 mg, 837 μl) was added to
a solution of isobutylamine (6.0 mmol, 439 mg, 597 μl) in
dichloromethane (30 ml). The mixture was cooled to 0 °C
using an ice bath. Decanoyl chloride (5.0 mmol, 954 mg,
1.0 ml) was slowly added to the solution. The mixture was
stirred overnight, allowing the temperature to rise to room
temperature. The reaction mixture was extracted with
50 ml dichloromethane which was washed successively
with HCl (1.0 M aq.) and NaHCO3 (sat. aq.). The organic
layer was dried on Na2SO4, filtered and concentrated in
vacuo to yield the title compound (1.07 g, 4.7 mmol) as an
off-white waxy solid. The compound was identified by 1H
and 13C NMR recorded with a Varian Mercury-300BB
(300/75 MHz) spectrometer. Chemical shifts are given
relative to tetramethylsilane (0 ppm) 1H NMR (300 MHz,
CDCl3): δ 5.47 (s, 1H), 3.07 (t, J = 6.45 Hz, 2H), 2.16 (t,
J = 7.44 Hz, 2H), 1.80–1.69 (m, 1H), 1.68–1.58 (m, 2H)
1.38–1.18 (m, 12H), 0.90 (d, J = 6.90 Hz, 6H), 0.87 (t, J =
6.90 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 173.25, 46.92,
37.16, 32.00, 29.61, 29.51, 29.47, 29.41, 28.67, 26.05, 22.80,
20.24, 14.24.
In vitro permeation study in Caco-2 cell monolayers
Cell culture
Caco-2 cells, originating from a human colorectal car-
cinoma were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) at 95 % humidity and 37 °C in an at-
mosphere of 5 % CO2, supplemented with 10 % (V/V)
fetal bovine serum, 2 mM L-glutamine and 1 % non-
essential amino acids (100x), 100 U/ml penicillin and
100 μg/ml streptomycin (all from Invitrogen/GIBCO,
Ghent, Belgium).
Caco-2 cell permeability assay
The Caco-2 cell intestinal model was used as a model
for the gut mucosa to investigate the permeation of spi-
lanthol. Caco-2 cells were seeded at a density of 2.6 · 105
cells/cm2 cells for each Transwell (Corning Costar, New
York, USA) membrane insert filter (0.4 μm pore size,
12 mm filter diameter) and cultivated in the described
supplemented DMEM, also containing 100 units/ml
penicillin and 100 μg/ml streptomycin. The medium was
changed every second day. The cells were allowed to
grow and differentiate for 21–29 days until monolayers
were formed. Intact membranes/integrity of the mono-
layers were checked via the measurement of transepithe-
lial electrical resistance (TEER) of the monolayers using
the Millicell-ERS system (Millipore Corp., Bedford, MA,
USA) before and after transport experiments. The experi-
ment was performed in duplicate for each dose solution.
Transport experiments were carried out in the apical-to-
basolateral (ab) direction and in the basolateral-to-apical
(ba) direction in Hanks’ Balanced Salt solution, according
to Hubatsch et al. [18]. Two dose solutions of purified spi-
lanthol at 10 μg/ml were tested, differing in solvent: 0.5 %
ethanol (further indicated as DS1) and 0.5 % of a mixture
of vitamin E-TPGS (33.3 %), ethanol (11.1 %), PEG 400
(33.3 %) and PG (22.2 %) (further indicated as DS2) dis-
solved in HBSS.
Final volumes of 0.4 ml apically and 1.2 ml basolater-
ally were used for 12-mm filter supports during the
transport experiment. Samples were taken at 15, 30, 60,
90 and 120 min from the acceptor (= receiver) com-
partment (basolateral to apical transport: 100 μl; apical
to basolateral transport: 300 μl) and were immediately
replaced by fresh HBSS. At the last time point, a sam-
ple from the donor compartment was taken as well,
allowing to obtain the mass balance, which for spi-
lanthol ranged between 104.7 and 120.9 % total recovery.
Atenolol (50 μM) and propranolol (20 μM) were used as
the low- and high-permeability control, respectively, con-
firming the validity of the test [19]. Quantification of spi-
lanthol was conducted using the UPLC-MS2 method as
described below.
The apparent permeability coefficient (Papp in cm/s) of
spilanthol was calculated from a non-sink equation.
From Fick’s first law: J = −D× [dC(x)]/dx (D is the diffu-
sion coefficient, J is the flux or transfer rate along the
donor-to-receptor side, x is the distance from the donor
compartment and C(x) is the concentration in the barrier
at the coordinate x in the barrier), the following differential
equation is derived: dMr(t)/dt = Papp ×A × [Cd(t) −Cr(t)], in
which Mr is the amount of substance in the receiver cham-
ber, Papp is the apparent permeability coefficient (a product
of distribution coefficient with diffusion coefficient divided
by the barrier thickness), A is the cross-sectional area of
Fig. 1 Synthesis of isobutyldecanamide (analytical internal standard)
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the barrier, Cd is the donor concentration and Cr is the re-
ceiver concentration. This differential equation is the basis
to calculate Papp values of compounds requiring sink, as
well as non-sink conditions with different initial conditions
to solve this equation. In the case of non-sink conditions,
this resulted in the following solution [18, 20]:
Cr tð Þ ¼ MVd þ Vr
 








in which t is the time (s), Vd is the volume of the donor
compartment (ml), Vr the volume of the receiver com-
partment (ml), A the area of the filter (= 1.12 cm2), M
the total amount of spilanthol in the system at time t
(μg), Cr,t-1 the concentration of spilanthol in the receiver
compartment at the previous time point (μg/ml), f is the
sample replacement dilution factor (1-Vs/Vr with Vs is
the sample volume), Δt is the time at time t minus the
previous time point (s) and Cr(t) the concentration of
spilanthol in the receiver compartment at time t (μg/ml).
Non-linear curve fitting by minimisation of the sum of
squared residuals (SSR) was used to obtain the Papp. The
efflux ratio is calculated as Papp,ba/Papp,ab, while the up-
take ratio is calculated as Papp,ab/Papp,ba.
In vivo pharmacokinetic experiment with rats
Animals
The Wistar rats were bred in Bharat Serum and Vac-
cines pvt. Ltd, Thane, India (registration number 103/
99/CPCSEA) and kept for the experiments at C. U.
Shah College of Pharmacy, SNDT Women’s University,
Santacruz, Mumbai, India (registration number 39/99/
CPCSEA). The half of the rats used in the experiment
were female rats and the other half male rats. Rats of 7-
8 weeks old, weighing 220 g, and fasted overnight were
used for the experiment.
Pharmacokinetic experiment
The pharmacokinetic oral gavage experiment was carried
out at C. U. Shah College of Pharmacy, SNDT Women’s
University, Santacruz, Mumbai, India. A spilanthol dose
solution was prepared with the Spilanthes acmella (L.) L.
extract (A.Vogel). 1.5 ml of a spilanthol dose solution of
0.73 mg spilanthol/g dose solution in 10:20:30:40 (w/w/w/
w) ethanol:PG:vitamin E-TPGS:PEG400 was administered
to the rats using a gavage needle made up of stainless steel
(length 3 inches and 2.5 mm internal diameter). A blank
dose solution was used as well, containing ethanol, PG,
vitamin E-TPGS and PEG without spilanthol. For each
dose solution, six rats were used of which three were fe-
males and three males. Blood was collected (1.5 ml) from
the retro orbital vein at specified time points i.e. 1, 2, 3, 4,
6, and 8 h after oral administration of the dose solution.
The collected blood samples were centrifuged using a
Remi R-24 centrifuge. At the end of the study, the animals
were sacrificed by CO2 inhalation. All samples were imme-
diately frozen at -80 °C until bio-analysis. The elimination
rate constant was calculated using a one compartmental
model using GraphPad software (La Jolla, USA), using the
following equation: C tð Þ ¼ C0  e−ket , in which t is time
(h), C0 the concentration of spilanthol at time t = 0 (ng/ml),
C(t) the concentration of spilanthol at time t and ke the
elimination rate constant (h−1). The elimination half-life (h)
is computed as ln(2)/ke.
In vivo blood-brain barrier experiment with mice
Animals
Female, Institute for Cancer Research, Caesarean Derived-1
(ICR-CD-1) mice (Harlan Laboratories, Venray, Netherlands)
of age 7–10 weeks and weighing 29–32 g, were used during
the BBB transport experiments. All animal experiments
were performed in accordance with the Ethical Committee
principles of laboratory animal welfare as approved by our
institute (Ghent University, Faculty of Veterinary Medi-
cine, no. EC2012/157 and no. EC2014/128).
Blood-to-brain transport
An in vivo multiple time regression (MTR) analysis was
performed to investigate if spilanthol was able to cross
the BBB. A dose solution of spilanthol was prepared
using the Spilanthes acmella (L.) L. extract (Robertet)
with a final concentration of 4 mg/ml spilanthol dis-
solved in 7.0 % ethanol, 2.5 % dimethylacetamide, 0.6 %
tween 80 (all w/w) diluted in lactated Ringer’s solution
containing 1 % BSA. The ICR-CD-1 mice were anesthe-
tized by intraperitoneal injection with a 40 % (w/V) ur-
ethane solution (3 g/kg) and the jugular internalis vein
and carotid artery were isolated, 20 μl of the spilanthol
dose solution was injected into the jugular vein. Blood
was obtained from the carotid artery at regular time
points after injection (1, 3, 5, 10, 12.5 and 15 min, with
start and end in duplicate), and the mice were immedi-
ately thereafter decapitated. After sacrificing the mice,
the brains were collected. The collected blood from the
carotid artery was centrifuged at 10 000 g for 15 min at
21 °C, resulting in serum. In order to assure the validity
of the MTR method, 125I-BSA and dermorphin diluted
in lactated Ringer’s solution containing 1 % BSA were
used as the negative and positive control, respectively
[21–23]. Furthermore, to evaluate the functional BBB in-
tegrity under our experimental conditions, 125I-BSA was
also administered to the mice in a solution containing
the same surfactant and co-solvents in equal concentra-
tions as in the spilanthol dose solution. The serum pro-
file of spilanthol was plotted against the time (expressed
in min). The curve was fitted using the same one com-
partmental model as described in the pharmacokinetic
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experimental section. In order to determine the BBB
permeability of a compound, the ratio of the brain and
serum concentration (μl/g) was plotted versus a derived
time variable, i.e. the exposure time (θ) of the Gjedde-
Patlak plot [24, 25].
The exposure time is defined as the integral of the con-
centration of spilanthol in serum from start (t = 0 min) to
time T, divided by the concentration of spilanthol in




CS Tð Þ . The integral of the
concentration of spilanthol in serum from zero to time T
is the area under the curve until time T.
A biphasic model of blood-brain transfer was used to
fit the uptake, as elaborated by Wong et al. [26]:
Cbrain Tð Þ
CS Tð Þ ¼ K θþ Vg  1−e
−θ K1−KVg
   !
þV0
K ¼ 0
≅ Vg  1−e
−θ K1Vg
   !
þ V0
where K1 is the unidirectional clearance (μl/(g · min)), K
is the net clearance (μl/(g · min)), Vg the tissue brain distri-
bution volume (μl/g), and V0 the vascular brain distribu-
tion volume (μl/g). The negative control BSA has a low
vascular distribution volume and this value (14.8 μl/g) is
used as V0 to calculate the brain kinetic parameters of
spilanthol. In the equation, Cbrain(T) is the concentration
of spilanthol in the brain at time T (ng/g) and Cs(T) the
concentration of spilanthol in serum at time T (ng/μl).
Capillary depletion
To investigate the distribution of spilanthol in the paren-
chyma and capillaries of the brain, a capillary depletion
experiment was performed. By means of this experiment,
it is possible to distinguish the transport of spilanthol
into the brain (represented by the parenchyma) and part
of spilanthol which is trapped by the endothelial cells of
the brain (represented by the capillaries). The method of
Triguero et al. [27], as modified by Gutierrez et al. [28],
was used [29]. Briefly, after anesthetizing the mice intra-
peritoneally with 40 % (w/V) urethane solution (3 g/kg),
20 μl of the 4 mg/ml spilanthol dose solution was injected
into the jugular vein. Blood was collected from the abdom-
inal aorta ten min after injection and serum was obtained
by centrifuging the blood at 10 000 g during 15 min at 21 °
C. Immediately after blood collection, the skin of the
mice’s chest is removed to clamp the aorta and the jugular
veins are severed. Immediately after clamping the aorta,
the brain is perfused manually with 20 ml of Lactated
Ringer’s solution. The mice are decapitated immediately
after perfusion and brain is collected. The brains were put
into an Eppendorf tube and weighed. 525 μl ice-cold
capillary buffer (10 mM HEPES, 141 mM NaCl, 4 mM
KCl, 2.8 mM CaCl2, 1 mM MgSO4, 1 mM NaH2PO4 and
10 mM D-glucose adjusted to pH 7.4) was added and ho-
mogenized. Then, 1000 μl of 26 % ice-cold dextrane solu-
tion in capillary buffer was added and vortexed. The
Eppendorf tube was centrifuged at 20 000 g for 60 min at
4 °C. Pellet (capillaries) and supernatant (parenchyma and
fat tissues) were separately collected into an Eppendorf
tube and weighed. The sample preparation of the pellet is
the same sample preparation method as used for the mice
brains, while the sample preparation for the supernatant is
the same sample preparation method as used for mice
serum, as described in the bio-analytical section below.
The distribution was calculated as follows:
Fraction %ð Þ ¼ Mtissue
Mcapillaries þMparenchyma  100
where Mtissue represents the amount of spilanthol in the
capillaries, respectively parenchyma; Mcapillaries the amount
of spilanthol in the capillaries and Mparenchyma the amount
of spilanthol in the parenchyma.
Brain-to-blood transport
To evaluate the efflux of spilanthol out of the brain, an in
vivo method previously described was used [29]. Briefly,
after anesthetizing the ICR-CD-1 mice using a 40 % (w/V)
urethane solution (3 g/kg), the skin of the skull was re-
moved. Thereafter, a hole was made into the lateral ven-
tricle using a 22 G needle marked with tape at 2 mm at
the following coordinates: 1 mm lateral and 0.34 mm pos-
terior to the bregma. 1 μl of the 4 mg/ml spilanthol dose
solution as used for the blood-to-brain influx experiment
was injected intracerebroventriculary (ICV) using a syr-
inge pump (KDS100, KR analytical, Cheshire, UK) at a
speed of 360 μl/h for 10 s. At specified time points post-
injection (1, 3, 5, 10, 12.5 and 15 min), mice were decapi-
tated. Prior to decapitation, blood was collected from the
abdominal aorta. Serum was obtained by centrifuging the
blood at 10 000 g during 15 min at 21 °C and brains were
collected. The efflux brain half-life (t1/2,brain) (min) was
calculated from the linear regression of the natural loga-
rithm of the spilanthol concentration in brain (ng/g)
versus time as follows: t1/2,brain = ln(2)/kout, where kout
(min−1) is defined as the efflux rate constant calculated as
the negative value of the slope of the linear regression, ap-
plying first order kinetics.
Bio-analytics
Serum sample preparation
60 μl of the serum samples, 60 μl of 4 % (V/V) aqueous
H3PO4 solution and 30 μl of the IS solution were trans-
ferred into a 0.5 ml (LoBind Eppendorf ) tube and vor-
texed. Interfering compounds were removed by solid
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phase extraction using a positive pressure-96 processor
(Waters). 100 μl (rat serum) or 125 μl (mice serum) of the
previous sample solution was loaded on the HLB Oasis®
μelution 96 well plate (Waters, Zellik, Belgium), which was
preconditioned with 200 μl of MeOH and equilibrated
using 200 μl of ultrapure water. After the loading step, the
HLB Oasis® μelution plate was washed using 200 μl of 5 %
MeOH in H2O followed by 200 μl of 20 % MeOH in H2O.
Spilanthol was eluted using two times 25 μl ACN. To the
eluate, 25 μl of a 80:20 (V/V) H2O:MeOH solution was
added and analysed with a UPLC-MS2 method, as further
described.
A basic validation of the bio-analytical method for the
quantification of spilanthol in serum was performed, based
upon the EMA guideline on bio-analytical method valid-
ation (EMEA/CHMP/EWP/192217/2009) [30]. The limit
of detection (LoD) (S/N = 3) and limit of quantification
(LoQ) (S/N = 10) of spilanthol, determined on the refer-
ence standard, were calculated as 0.09 ng/ml and 0.31 ng/
ml, respectively, which correspond to 0.17 ng/ml and
0.58 ng/ml in rat serum, respectively. The LoD and LoQ of
spilanthol in mouse serum were 0.048 ng/ml and 0.16 ng/
ml, respectively. A matrix factor of 1.1 was observed for
spilanthol in rat and mouse serum. The quantification of
spilanthol in the rat serum samples was performed using a
matrix spiked calibration curve (R2 = 0.9998). Linearity was
assured in a working range from 0.31 ng/ml up to 101 ng/
ml, corresponding to 0.58 ng/ml to 189 ng/ml in rat serum.
The quantification of spilanthol in the mouse serum sam-
ples was performed using a one-point calibration curve
with a spilanthol standard in 40:33.33:26.67 (V/V/V) MeO-
H:ACN:H2O. The accuracy of the references used for the
calibration curves with the pre-extracted spiked matrix
samples and the QC reference pre-extracted spiked matrix
samples conformed to the specification limits (< 15 % of
the nominal value and for the lower limit of quantification
(LLoQ) < 20 % of the nominal value), except for the
LLoQ used for the validation of spilanthol in mouse
serum (> 20 % of the nominal value). These values are
slightly higher than the specification limits given by the
EMA in their guidelines for formal bio-analytical method
validation, but are still acceptable for our purposes in the
discovery phase. Precision was expressed as the coefficient
of variation (CV). The within-run CV value did not ex-
ceed 15 % for the pre-extracted spiked matrix samples.
Also the LLoQ did not exceed 20 % and are thus all con-
form to the specification limits. The recovery in rat serum
was 102.1 % (18.8 ng/ml to 189 ng/ml in serum concen-
tration range), calculated from the slopes of the pre-
extracted and post-extracted spiked matrix samples. The
recovery in mouse serum was 113.3 % (3 to 257 ng/ml in
serum concentration range). No significant carry-over was
observed (< 20 % of LLoQ spilanthol and < 5 % for IS).
The selectivity was conform to the specification limits
(placebo rat serum < 20 % of LLoQ spilanthol and < 5 %
for IS).
Brain sample preparation
For the analysis of the mice brain samples, the weighed
brains were transferred into a test tube and crushed.
1.0 ml of the IS solution in ACN was added, followed by
shaking during 4 h at 110 rpm at room temperature using
an Eppendorf centrifuge 5810 (Eppendorf, Rotselaar,
Belgium). The test tube was centrifuged at 250 g for 5 min
and 800 μl of the supernatant was transferred into an
Eppendorf tube. Thereafter, a second centrifugation was
performed at 20 000 g during 5 min at room temperature.
750 μl of the supernatant was evaporated to dryness under
nitrogen and 175 μl 90:10 (V/V) H2O:ACN was added to
redissolve spilanthol. Thereafter, 160 μl of this solution
was loaded on the HLB Oasis® μelution 96 well plate. The
same washing and elution steps were used as for the
serum samples.
Again, a basic validation of the bio-analytical method for
the quantification of spilanthol in brains was performed,
based upon the EMA guideline on bio-analytical method
validation (EMEA/CHMP/EWP/192217/2009) [29]. The
LoD and LoQ of spilanthol were 6.30 pg/g in brain and
21.0 pg/g in brain, respectively. Ion enhancement (matrix
factor = 1.38 > 1) was observed for the quantification of
spilanthol in mice brains. Hence, quantification of spi-
lanthol in the brain samples was performed using the
matrix spiked calibration curve (R2 = 0.9986). Linearity
was assured in a working range of 0.107 ng/ml to 175 ng/
ml spilanthol, corresponding to 21.0 pg/g to 34.3 ng/g in
brain. The accuracy of the references used for the calibra-
tion curves with the pre-extracted spiked matrix samples
conformed to the specification limits (< 15 % of the nom-
inal value), except for the LLoQ used for the validation of
spilanthol in brains (> 20 % of the nominal value), but was
still acceptable for our purposes in the discovery phase.
The within-run CV value did not exceed 15 % for the pre-
extracted spiked samples. Also the LLoQ did not exceed
20 % and are thus all conform to the limits. The recovery
in mouse brains was 72.7 % (0.92 to 98.10 ng/g brain con-
centration range).
UPLC-MS2 method
Quantification of spilanthol was performed using a UPLC-
MS2 method, which was developed on an Acquity UPLC
coupled to a Xevo™ TQ-S mass spectrometer (MS) (Waters,
Zellik, Belgium) with electrospray ionisation source and a
triple quadrupole mass analyser. An Acquity UPLC RP C18
column (Waters, 50 x 2.1 mm, 1.7 μm) with a suitable
guard column was used. The sample compartment was
kept constant at 5 °C, while the column temperature was
maintained at 30 °C. 2 μl of the sample was injected and
the flow rate was set to 0.5 ml/min. A mobile phase was
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applied using solvent A (0.1 % FA in 30:70 (V/V)
H2O:MeOH) and solvent B (0.1 % FA in MeOH) in
gradient mode as follows: 0–1.6 min 100:0 (V/V) A:B,
1.6–2 min going from 100:0 (V/V) A:B to 0:100 (V/V)
A:B, 2–3 min 0:100 (V/V) A:B, 3–3.4 min going from
0:100 (V/V) A:B to 100:0 (V/V) A:B, 3.4–5 min 100:0
(V/V) A:B. The needle wash solvent was 60:40 (V/V)
DMSO:ACN. The MS was operated in the positive electro-
spray ionisation mode (ESI+), with an optimised capillary
voltage of 3.0 kV, cone voltage of 50 V and source offset of
60 V. Source and desolvation temperatures were set at
150 °C and 500 °C, respectively, while cone and desolva-
tion gas (N2) flows were 180 and 1000 l/h, respectively.
Acquisition was performed in the multiple reaction
monitoring (MRM) mode with m/z 222.15 to m/z 80.96
transition. The applied collision energy was 20 eV (col-
lision gas = argon). Data were acquired and analysed
through MassLynx® software (V4.1 SCN 843, Waters).
Results
Caco-2 cell permeability
Propranolol was used as a positive control and a Papp,ab
value of 19.1 · 10−6 cm/s was obtained, which is in good
agreement with the values reported in literature [31]. Aten-
olol served as the negative control and a lower permeability
was observed compared to propranolol. Spilanthol was
able to diffuse through the Caco-2 cell monolayer from the
apical-to-basolateral side, as well as from the basolateral-
to-apical side. Figure 2 shows the percentages of spilanthol
permeated through the Caco-2 cells versus time plot with
DS1 and DS2.
The percentage of the applied spilanthol which perme-
ated through the Caco-2 cells from the apical-to-basolateral
membrane after 120 min is 79.8 % (or 3.20 μg spilanthol)
with DS1 and 64.3 % (or 2.47 μg spilanthol) with DS2. In
the opposite direction, the percentage of spilanthol
which permeated through the Caco-2 cells from the
basolateral-to-apical membrane after 120 min is 32.1 %
(or 3.86 μg spilanthol) with DS1 and 21.6 % (or 2.49 μg
spilanthol) with DS2.
The apparent permeability coefficient (Papp) of spilanthol
obtained with DS1 and DS2 from the apical-to-basolateral
side is 8.42 ± 0.59 · 10−5 cm/s (mean ± SD, n = 2) and 5.61
± 0.54 · 10−5 cm/s (mean ± SD, n = 2), respectively. The
Papp of spilanthol obtained with DS1 and DS2 was also de-
termined from the basolateral-to-apical side and is 10.21 ±
0.46 · 10−5 cm/s (mean ± SD, n = 2) and 5.20 ± 0.06 · 10−5
cm/s (mean ± SD, n = 2), respectively. The efflux ratio for
spilanthol with DS1 and DS2 is 1.21 and 0.93, respectively,
while the uptake ratio for spilanthol with DS1 and DS2 is
0.82 and 1.08, respectively.
Oral gavage experiment
Figure 3 represents the rat serum data after oral gavage
of spilanthol, fitting a one compartmental model with
the mean concentration of spilanthol at each time point.
Fig. 2 Apical-to-basolateral transport and basolateral-to-apical transport of spilanthol in DS1 and DS2
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These results of the in vivo experiment confirm the in
vitro Caco-2 cell monolayer results of spilanthol.
From these data, the elimination rate constant and the
elimination half-life were calculated as 0.61 h−1 and
1.13 h, respectively.
Blood-brain barrier transport kinetics of spilanthol
The blood-to-brain transport of spilanthol was investi-
gated. The negative and the positive control confirmed
the validity of the BBB test. The K1 value of BSA (nega-
tive control) was 0.12 μl/(g · min), while the K1 value of
the positive control dermorphin was 0.26 μl/(g · min),
both consistent with previous data [29, 32]. The multiple
time regression data indicated that spilanthol crosses the
blood-brain barrier. In Fig. 4, the ratio of the concentra-
tion of spilanthol in brain and serum is plotted versus
the exposure time. Furthermore, the kinetic influx data
of 125I-BSA with or without the surfactant/so-solvents
were not significant different, indicating that the surfac-
tant and co-solvents did not affect the BBB integrity
(data not shown).
The MTR data of spilanthol were fitted using a biphasic
model, based on the modified Gjedde-Patlak equation ac-
cording to Wong et al. [26]. A rapid but highly significant
influx of spilanthol into the brains was observed with a
unidirectional influx rate (K1) of 796 μl/(g · min). The tis-
sue brain distribution volume (Vg) is 652 μl/g.
The curve reached a plateau-phase after about 10 min
exposure time and can be explained by efflux of spi-
lanthol out of the brain.
At the same time, also the elimination kinetics of spi-
lanthol in serum were evaluated in the mice model. The
serum profile of spilanthol follows a one compartmental
model. The concentration of spilanthol at time zero was
3.05 μg/ml and an elimination rate constant and elimin-
ation half-life of 0.22 min−1 and 3.16 min were obtained.
Capillary depletion
The capillary depletion method was used to study the dis-
tribution of spilanthol i.e. the part that was taken up by
the brain and the part which was trapped in the endothe-
lial cells of the brain capillaries. A high brain penetration
of spilanthol was found: about 98 % of spilanthol (corre-
sponding to 137.8 μl/g) was found in the brain paren-
chyma and only about 2 % of spilanthol (corresponding to
2.4 μl/g) that entered the brain remained in the brain
capillaries.
Brain-to-blood transport kinetics of spilanthol
The efflux properties of spilanthol out of the brain were
investigated by quantifying the concentration of spilanthol
in the brain after intracerebroventricular injection of the
dose solution. When evaluating the transport of spilanthol
out of the brain into the blood, it is confirmed that there is
also efflux of spilanthol (Fig. 5), which can explain the
rapid plateauing observed when evaluating the blood-to-
brain kinetics during the influx experiment (Fig. 4). The ef-
flux transfer constant kout was derived from the absolute
value of the slope of the natural logarithm of the concen-
tration of spilanthol in the brain (ng/g) versus the experi-
mental time curve (min). The kout calculated for spilanthol
was 0.11 min−1, equal to a t1/2,brain of 6.4 min.
Discussion
In this study, the in vitro Caco-2 cell monolayer perme-
ability of spilanthol, a 2,6,8-triene NAA, was investigated
using two different dose solutions. The permeation level
of spilanthol through Caco-2 cells was the highest from
the apical-to-basolateral side: 64–80 % of the applied DS
permeated through Caco-2 cells after 120 min (absorp-
tive direction). Spilanthol, applied as DS2, did not appear
to better permeate the Caco-2 cells compared to
spilanthol applied as DS1, suggesting that co-solvents
(vitamin E-TPGS, PEG 400, PG) did not enhance the
Fig. 3 Concentration of spilanthol in rat serum as a function of time after oral gavage, one compartmental model (n = 3, mean, error bars: SEM)
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permeation of spilanthol through the cell monolayer.
Both dose solutions did not contain more than 0.5 %
ethanol in buffer, as final ethanol concentrations above
2 % can damage the Caco-2 cell monolayer.
As mentioned earlier, Matthias et al. [15] investigated a
different type of NAA, namely the transport of 2-ene and
2,4-diene NAAs through the Caco-2 cell monolayer (dis-
solved in ethanol and diluted in HEPES buffer, final etha-
nol concentration did not exceed 2 %) with Papp values
ranging from 3 · 10−6 to 3 · 10−4 cm/s. The diversity in Papp
for the different N-alkylamides was correlated to struc-
tural variations, with saturation and N-terminal methyla-
tion contributing to lowered Papp values.
The Papp values obtained for spilanthol in this study were
all above 1 · 10−6 cm/s, indicating an almost complete intes-
tinal absorption. Compounds with Papp values < 1 · 10
−6
cm/s show a less readily absorption. The Papp values ob-
tained for spilanthol in this study (5 · 10−5 to 10 · 10−5 cm/s)
are thus consistent with the structural conclusions reported
by Matthias et al. [15] based on the mono- and diene-
NAAs from Echinacea plant species.
It has been reported that if there is a more than 2-fold
difference in Papp values between the apical-to-basolateral
and the basolateral-to-apical direction, a high probability
of active transport exists [33]. In this experiment, for both
dose solutions of spilanthol, this difference was less than
2-fold, indicating that no active transport function can be
readily assumed. Studies have proven a correlation be-
tween drug permeability coefficients obtained during a
Caco-2 cell monolayer experiment and oral absorption in
humans [31, 34, 35]. However, as no in vitro model can
yet totally mimic the in vivo intestinal barrier, since many
factors such as solubility, formulation, chemical compos-
ition, pH of the intestinal secretions, food composition,
gastric emptying time, intestinal motility and blood flow
play a role [33, 36, 37], an oral gavage experiment in rats
was conducted to evaluate the intestinal barrier properties
of spilanthol in vivo. Rats are one of the most common
Fig. 4 Brain influx results of spilanthol, BSA and dermorphin (MTR in mice)
Fig. 5 Brain efflux of spilanthol
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animals used in preclinical oral absorption studies [36]
and are generally considered as good animal models to-
wards humans (e.g. F1 modifying factor in permitted daily
exposure (PDE) toxicity evaluation is 5 for extrapolation
from rats to humans) [38]. Several studies have already
shown that there is a good correlation between the absorp-
tion of compounds in rat and the absorption in humans
[36, 37, 39]. Spilanthol was orally administered to rats in a
liquid dose solution containing the same solvents as used
for DS2 of the Caco-2 cell permeability experiment, con-
sisting of ethanol, PG, vitamin E-TPGS and PEG400. For
the absorption rate, the formulation plays an important
role and compounds solubilized in liquid generally absorb
faster compared to solid forms. The elimination phase, on
the contrary, is independent of the oral dosage form. Vita-
min E-TPGS, an esterified vitamin E derivative, was added
to the formulation because of its solubilizing and emulsify-
ing properties to enhance the solubility and facilitate the
absorption of spilanthol [40, 41]. In this in vivo study, spi-
lanthol was clearly observed in the rat serum and hence,
spilanthol was able to diffuse through the gut barrier into
the systemic circulation, confirming the in vitro Caco-2
cell results. Spilanthol showed an elimination half-life of
1.13 h (63 min), corresponding to similar values reported
by Woelkart et al. [17], who investigated the plasma con-
centration of dodeca-2E,4E,8E,10E/Z-tetraenoic acid iso-
butylamides from Echinacea via oral gavage in rats,
resulting in an elimination half-life of 72 min.
Besides the lipophilicity of the compound, its passive
gut-blood permeability is dependent on the charge and
molecular size of the compound. Considering the lipo-
philic LogP value of 3.39 of spilanthol and the molecular
weight of 221.34 g/mol, it seems that transcellular trans-
port is appropriate for spilanthol [42]. These findings
were confirmed in the Caco-2 cell permeability experi-
ment, which indicated that spilanthol diffused through
the cells via passive diffusion. Once in the systemic cir-
culation, the investigated compound can distribute to
extravascular compartments such as the brain to exert
CNS activity.
Therefore, the present study investigated the blood-
brain barrier transport properties of spilanthol in an in
vivo mice experiment. In kinetic BBB research, one of the
‘golden’ methodologies is the MTR using mice for reasons
of costs, handling and animal care. In PDE toxicity evalu-
ation, the F1 modifying factor is 12 for extrapolation from
mice to humans [38]. Spilanthol was administered to the
mice in a solution containing ethanol, dimethylacetamide
and tween 80 in lactated Ringer’s solution containing BSA.
Dimethylacetamide and ethanol are often used in inject-
able pharmaceutical formulations as co-solvents to
solubilize poorly soluble compounds, while tween 80 is a
traditional surfactant [43, 44]. It is known that tween 80 in
high doses up to 30 mg/kg administered to mice causes
blood-brain barrier disruption [45]. In this MTR study, a
dose of 3 mg/kg tween 80 was used. Also ethanol, at a
concentration of 1-4 g/kg, may cause disruption of the
BBB as well [45]. However, in the current study, only
0.04 g ethanol/kg mice was administered. Although transi-
ent effects cannot be excluded, our data indicate that the
solvents did not affect the BBB integrity. In addition, no
toxicity was observed during the experiment. From our re-
sults, it is concluded that spilanthol was able to rapidly
penetrate the BBB after intravenous administration with a
unidirectional influx rate of 796.2 μl/(g · min). This high
K1 value indicates a high initial influx rate of spilanthol
into the brains, which is supported by the lipophilic
character of this NAA. Moreover, 98 % of spilanthol
was found in the parenchyma of the brains, while only
2 % was trapped in the capillaries, which makes it pos-
sible for NAAs to exert CNS effects. Furthermore, sig-
nificant efflux out of the brain into the blood was also
observed.
It was already mentioned in the introduction that Spi-
lanthes acmella extracts showed some central analgesic
activities. In general, different central nervous pharma-
codynamic activities are attributed to N-alkylamide con-
taining plants. Psychotropic effects (anxiolytic effect) in
animals were already found by using alkylamide Echin-
acea preparations, which was explained by their affinity
for the CB receptors. Furthermore, similar to cannabi-
noids, alkylamides alter immune cell activity, which open
perspectives for the treatment of neuroinflammatory dis-
eases [17, 46]. In addition, capsaicin, the major NAA in
hot peppers of the plant genus Capsicum interacts ago-
nistically with the transient receptor potential vanilloid 1
receptor, predominantly expressed in primary afferent fi-
bres and sensory neurones, playing a role in pain sensa-
tion [47, 48]. Another study reported an improvement of
amyloid beta(1–42)-induced spatial memory impairment
after administration of a 50 mg/kg and 100 mg/kg meth-
anolic extract of Piper nigrum fruits by gastric gavage to
rats. The plant extract, containing piperine, which is a
major alkylamide of black pepper, caused an attenuation
of the oxidative stress in the rat hippocampus. Other stud-
ies demonstrated analgesic, anticonvulsant, antidepres-
sant, anti-oxidant, anti-inflammatory, protection against
neurodegeneration and cognitive enhancing effects of
cognitive deficit-like condition of Alzheimer’s disease of
piperine [49, 50].
In addition, in some studies there is an indirect proof
of blood-brain barrier influx of N-alkylamides. It has
been shown that several N-alkylamide containing plants
showed activity against epilepsy in animal models. Ex-
periments with medicinal plants such as Anacyclus pyr-
ethrum, Nigella sativa, Ferula gummosa and Pimpinalla
anisum were performed to investigate their effect on sei-
zures of epilepsy. It has been shown that the chloroform
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fraction of Anacyclus pyrethrum roots, 100–800 mg/kg ad-
ministered intraperitoneally to mice, possess neuropharma-
cological effects, such as antiseizure activity [51, 52]. Other
studies demonstrated the myorelaxation and anticonvulsant
activities in mice of the Anacyclus pyrethrum extract as well
[51, 53]. Treatment with capsaicin resulted in a decrease in
behavioral seizure activity and body temperature in a kainic
acid induced epileptogenesis mice model. Furthermore,
anti-oxidant activity in blood increased and the concentra-
tions of IL-1β and TNF-α in the brain lowered [48].
The majority of the studies reported in literature only
look at the effects of in vivo or in vitro studies and no ex-
posure data are available. Therefore, more detailed studies
about exposure levels are required. In the current study,
spilanthol concentrations in brains and serum were quan-
titatively measured and we demonstrated a high influx of
spilanthol into the brain, indicating a possible role in CNS
diseases.
Conclusion
In this study, it is demonstrated that spilanthol is able to
cross the Caco-2 cell monolayer in vitro and the intestinal
membrane in vivo in rats after oral administration. After
absorption and reaching the systemic circulation, spi-
lanthol is able to rapidly and significantly cross the BBB in
mice. Spilanthol also showed a significant efflux out of the
brain, which explains partly the biphasic behavior of the
influx. These results suggest possible medicinal applica-
tions for spilanthol in central nervous system diseases
from a pharmacokinetic point of view.
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